Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8007116 | 0.88 | EPHX1 (0.52) | CHRM1EPHX2EPHX1 | |
| SCHEMBL27669922 | 0.82 | GNAI3 (0.54) | CCR1GNAI3GNAO1GNAI1EPHX2 | |
| SCHEMBL12304475 | 0.81 | KDM4E (0.55) | CHRM1EPHX2EPHX1HTR4 | |
| SCHEMBL22951185 | 0.80 | HTR4 (0.46) | CHRM1EPHX2HTR4KCNH2 | |
| SCHEMBL25567991 | 0.80 | CHRM1 (0.46) | CHRM1 | |
| SCHEMBL4193160 | 0.79 | EPHX1 (0.60) | EPHX2EPHX1 | |
| SCHEMBL22305610 | 0.79 | CHRM1 (0.45) | CCR1CHRM1HTR4 | |
| SCHEMBL22519371 | 0.78 | CHRM1 (0.45) | CHRM1EPHX2EPHX1 | |
| SCHEMBL12304479 | 0.78 | HTR4 (0.49) | CHRM1HTR4 | |
| SCHEMBL17937231 | 0.77 | NPSR1 (0.53) | CCR1GNAI3GNAO1GNAI1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | CCR1 1208/4885GNAI3 1117/4885GNAO1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.